Measles-containing-vaccine first-dose (MCV1) immunization coverage in Senegal
Senegal: Measles-containing-vaccine first-dose (MCV1) immunization coverage was 92.0% in 2025. ▲ Rising
Measles-containing-vaccine first-dose (MCV1) immunization coverage in Senegal, 2000–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for measles-containing-vaccine first-dose (mcv1) immunization coverage in Senegal is 92.0%, measured in 2025.
Compared with earlier readings it is up 5.7% on the previous year and up 15.0% over ten years.
Over the whole period, measles-containing-vaccine first-dose (mcv1) immunization coverage in Senegal peaked at 93.0% in 2016 and was at its lowest, 48.0%, in 2000.
That places Senegal 82nd out of 194 countries with data for 2025, putting it in the middle of the range.
The long-run direction has been consistently rising across the 26 years of available data.
Measles-containing-vaccine first-dose (MCV1) immunization coverage in Senegal, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 48.0% | — |
| 2001 | 48.0% | +0.0% |
| 2002 | 54.0% | +12.5% |
| 2003 | 60.0% | +11.1% |
| 2004 | 57.0% | -5.0% |
| 2005 | 74.0% | +29.8% |
| 2006 | 80.0% | +8.1% |
| 2007 | 84.0% | +5.0% |
| 2008 | 77.0% | -8.3% |
| 2009 | 79.0% | +2.6% |
| 2010 | 81.0% | +2.5% |
| 2011 | 84.0% | +3.7% |
| 2012 | 83.0% | -1.2% |
| 2013 | 84.0% | +1.2% |
| 2014 | 80.0% | -4.8% |
| 2015 | 80.0% | +0.0% |
| 2016 | 93.0% | +16.2% |
| 2017 | 90.0% | -3.2% |
| 2018 | 86.0% | -4.4% |
| 2019 | 86.0% | +0.0% |
| 2020 | 82.0% | -4.7% |
| 2021 | 88.0% | +7.3% |
| 2022 | 87.0% | -1.1% |
| 2023 | 87.0% | +0.0% |
| 2024 | 87.0% | +0.0% |
| 2025 | 92.0% | +5.7% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 66.1% | 48.0% | 84.0% | 10 |
| 2010s | 84.7% | 80.0% | 93.0% | 10 |
| 2020s | 87.2% | 82.0% | 92.0% | 6 |
Countries ranked near Senegal
More health data for Senegal
- Un projection of annual infant deaths, annual growth rate -1.58 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.7598 % change on previous year (2090)
- Heat deaths vs projected death rates 835.5 (2090)
- Un projection of annual infant deaths 2,496 (2100)
- Population ages 0-14, total, annual growth rate 1.15 % change on previous year (2025)
- Population ages 0-14, total, per unit of GDP 0.0002 units per US$ of GDP (2025)
- Population ages 0-14, total, per capita 0.3774 units per person (2025)
- Population ages 15-64, female, annual growth rate 3 % change on previous year (2025)
- Population ages 15-64, female, per unit of GDP 0.0001 units per US$ of GDP (2025)
- Population ages 15-64, female, per capita 0.2912 units per person (2025)
Frequently asked questions
- What is measles-containing-vaccine first-dose (mcv1) immunization coverage in Senegal?
- Measles-containing-vaccine first-dose (mcv1) immunization coverage in Senegal was 92.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest measles-containing-vaccine first-dose (mcv1) immunization coverage recorded in Senegal?
- The highest recorded value was 93.0% in 2016.
- What is the lowest measles-containing-vaccine first-dose (mcv1) immunization coverage recorded in Senegal?
- The lowest recorded value was 48.0% in 2000.
- How does Senegal rank for measles-containing-vaccine first-dose (mcv1) immunization coverage?
- Senegal ranks 82nd out of 194 countries with data for 2025.
- Is measles-containing-vaccine first-dose (mcv1) immunization coverage rising or falling in Senegal?
- Over the last ten years it is up 15.0%. The long-run trend across the full record is rising.
- Where does this Senegal data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 26 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).